Revisiting the Concept of Recurrence of Primary Central Nervous System Lymphomas After Complete Response to Methotrexate-Based Therapy: Periventricular Reseeding as the Predominant Mechanism of Recurrence

Tugce Kutuk; G Daniel Grass; Daniel Oliver; Sepideh Mokhtari; Solmaz Sahebjam; Sungjune Kim; Jose Penagaricano; Hsiang-Hsuan Michael Yu; Nam Tran; Arnold Etame; Jennifer L Peterson; Peter Forsyth; Timothy Robinson

doi:10.1016/j.adro.2022.100940

Revisiting the Concept of Recurrence of Primary Central Nervous System Lymphomas After Complete Response to Methotrexate-Based Therapy: Periventricular Reseeding as the Predominant Mechanism of Recurrence

Adv Radiat Oncol. 2022 Mar 9;7(4):100940. doi: 10.1016/j.adro.2022.100940. eCollection 2022 Jul-Aug.

Affiliations

¹ Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
² Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
³ Department of Neurosurgery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
⁴ Department of Radiation Oncology, Mayo Clinic Cancer Center, Jacksonville, Florida.
⁵ Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA.

Abstract

Purpose: Understanding patterns of relapse for primary central nervous system lymphoma (PCNSL) may inform mechanisms of recurrence and optimal consolidation strategies. In this study, we report patterns of relapse among patients with PCNSL who achieved a complete response to high-dose methotrexate (HD-MTX)-based chemotherapy with or without consolidation radiation therapy (RT).

Methods and materials: We conducted an institutional retrospective analysis of patients with PCNSL who received HD-MTX-based chemotherapy between November 2001 and May 2019. Relapses were characterized as in-field (within original T1 contrasted lesion), marginal (within T2 fluid-attenuated inversion recovery but not T1), local (in-field or marginal), distant brain (no overlap), or distant (distant brain, cerebrospinal fluid, vitreous or extra-axial) and further characterized with respect to periventricular location (≤10 mm of ventricles).

Results: Seventy-eight patients with PCNSL met inclusion criteria, of whom 29 (37%) underwent consolidation RT. Median progression-free survival and overall survival were 57.0 and 66.7 months, respectively. After a median follow-up of 38.9 months, a total of 32 patients (41%) experienced recurrence. Most patients (21 [65.6%]) had a periventricular failure. Surprisingly, local recurrences (n = 11) were exclusively observed within periventricular lesions, whereas distant recurrences (n = 21) were seen in both periventricular and nonperiventricular locations (P = .009). The median time to progression was shorter for locally recurrent lesions compared with distant recurrences (13.8 vs 26.1 months; P = .03).

Conclusions: After complete response to HD-MTX, few failures occurred within initial T1 contrast-enhancing lesions and many of these may have been alternatively classified as periventricular failures. These observations argue against the use of purely focal RT consolidation for patients who achieve a complete response after HD-MTX-based chemotherapy and suggest that periventricular reseeding may have a central role in PCNSL recurrence.